{"id":"sr-b-epratuzumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108404","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epratuzumab is a monoclonal antibody that binds to CD22, a B cell-restricted antigen, leading to B cell modulation and reduced autoimmune activity. The SR-B component likely refers to a specific formulation or combination strategy to enhance therapeutic efficacy in systemic lupus erythematosus and related autoimmune disorders.","oneSentence":"SR-B combined with epratuzumab targets B cell surface antigens to modulate immune response in autoimmune and inflammatory conditions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:36:02.559Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus (SLE)"},{"name":"Lupus nephritis"}]},"trialDetails":[{"nctId":"NCT07476729","phase":"PHASE3","title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-04-01","conditions":"B-Cell Acute Lymphoblastic Leukaemia","enrollment":750},{"nctId":"NCT01802814","phase":"PHASE3","title":"International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2014-05","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":700}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Epratuzumab"],"phase":"phase_3","status":"active","brandName":"SR-B + Epratuzumab","genericName":"SR-B + Epratuzumab","companyName":"Charite University, Berlin, Germany","companyId":"charite-university-berlin-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epratuzumab is an antibody that targets the B-cell receptor CD22, acting as a CD22 inhibitor. It has been studied in combination with SR-B in clinical trials for the treatment of Acute Lymphoblastic Leukemia (ALL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}